Last updated on February 2018

The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes

Brief description of study

The purpose of this study is to conduct an interventional, one year, randomized, double blind, placebo-controlled trial with Liraglutide in patients with type 2 diabetes (diabetes duration of >6 months and <10 years, HbA1c <10%) to evaluate its effects on the peripheral autonomic nervous system, as well as inflammatory markers, and measures of oxidative and nitrosative stress.

Detailed Study Description

We propose to examine the effects of GLP-1 receptor agonist Liraglutide on autonomic sudomotor function and endothelial and neurovascular functions as well as markers of inflammation in patients with type 2 diabetes mellitus. The primary objective will be changes in peripheral autonomic function using sudorimetry (Sudoscan) after 1 year of treatment.

The secondary objectives will be changes on markers of inflammation and oxidative/nitrosative stress including C-reactive protein (CRP) IL-1, IL6, IL12, IL10, Tumor Necrosis factor (TNF ), Plasminogen Activator Inhibitor 1 (PAI-1), Superoxide dismutase (SOD), nitrotyrosine, carboxymethyl-lysine (CML), Thiobarbituric Acid Reactive Substances (TBARS), and Asymmetric dimethylarginine (ADMA).

Additional objectives will include changes in neurovascular and endothelial function, measured by continuous Laser Doppler assessment of skin blood flow in response to different stimuli; and changes in sensory-motor peripheral nerve function, measured by clinical neuropathy scores (NSS & NIS), quantitative sensory testing and nerve conduction testing.

The aim of this study is to capture patients early in the disease process, when autonomic dysfunction is still potentially reversible. Several studies have shown the presence of autonomic imbalance in the early stages of DM and even in the prediabetic state (IGT, IFG and metabolic syndrome). We hypothesize that by treating type 2 diabetic patients with Liraglutide early in the disease process (<10 years of diagnosis), we will be able to improve peripheral autonomic imbalance, endothelial and neurovascular function, and reduce inflammation and oxidative/nitrosative stress. This will shed further insight into the mechanisms by which GLP-1 exerts a neuroprotective role and improves the inflammatory process. The possibility of improving autonomic imbalance, endothelial function and inflammation may have important impact in the development of new potential therapeutic strategies to abrogate the microvascular complications of diabetes

Clinical Study Identifier: NCT03426085

Contact Investigators or Research Sites near you

Start Over

Aaron I Vinik, MD, PhD

Strelitz Diabetes Center
Norfolk, VA United States
  Connect »